



**PRESS RELEASE**  
PledPharma AB

## Changes in PledPharma's Board of Directors and committees

**Stockholm, July 30, 2020. PledPharma AB (STO: PLED) today announced that Marie Ekström Trägårdh has chosen to step down from the company's Board of Directors due to private reasons.**

The duties and responsibilities of the Remuneration Committee and the Audit Committee will from now be taken on by the Board of Directors. Members of both these committees consisted previously of Håkan Åström, Chairman of the Board, and Marie Ekström Trägårdh.

**For further information, please contact:**  
Nicklas Westerholm, CEO  
Tel. +46 (0)73 354 20 62  
[nicklas.westerholm@pledpharma.se](mailto:nicklas.westerholm@pledpharma.se)

*The information was submitted for publication, through the agency of the contact persons set out above, at 2020-07-30, 08:00 CET.*

### About PledPharma

PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need. The company's project **PledOx**<sup>®</sup> is a first in class drug candidate and is being developed to prevent nerve damage associated with chemotherapy. The phase III program was recently stopped with a data cut-off targeted for the third quarter 2020. The drug candidate **Aladote**<sup>®</sup> is a first in class drug candidate and is being developed to reduce the risk of acute liver injury associated with paracetamol poisoning. A proof of principle study has been successfully completed, and the design of the next study is being finalised. Aladote<sup>®</sup> has been granted Orphan Drug Designation in the US. PledPharma (STO: PLED) is listed on the Nasdaq Stockholm main market since October 31, 2019. For more information, see <http://www.pledpharma.com/>